China Approves New Alzheimer’s Disease Drug: Here’s What to Know
Drug regulators in China have granted conditional approval to a new Alzheimer’s drug, the first such approval in nearly two decades. China’s National Medical Products Administration (NMPA) reportedly gave approval to Oligomannate (otherwise referred to as GV-971), developed by Chinese company Shanghai Green Valley Pharmaceuticals, for the treatment of mild to moderate Alzheimer’s disease and improving cognitive
Read more
Most Commented